Secnidazole: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Intestinal amoebiasis

Adult: As tab: 2 g as single dose. Treatment recommendations may vary among countries and available products. Consider local treatment or detailed product guidelines on the appropriate use or recommendations.
Child: As tab: 30 mg/kg as single dose.

Oral
Hepatic amoebiasis

Adult: As tab: 1.5 g daily as single or in divided doses for 5 days. Treatment recommendations may vary among countries and available products. Consider local treatment or detailed product guidelines on the appropriate use or recommendations.
Child: As tab: 30 mg/kg daily as single or in divided doses for 5 days.

Oral
Bacterial vaginosis

Adult: As granules or tab: 2 g as single dose. Treatment recommendations may vary among countries and available products. Consider local treatment or detailed product guidelines on the appropriate use or recommendations.

Oral
Trichomoniasis

Oral
Giardiasis

Child: As tab: 30 mg/kg as single dose. Treatment recommendations may vary among countries and available products. Consider local treatment or detailed product guidelines on the appropriate use or recommendations.

Reconstitution

Granules: Sprinkle contents onto applesauce, yoghurt, or pudding.

Contraindications

Hypersensitivity to secnidazole or other nitroimidazole derivatives. Lactation.

Special Precautions

Children. Pregnancy. Avoid chronic use. Granules are not intended to be dissolved or administered in any liquid.

Adverse Reactions

Significant: Vulvovaginal candidiasis.
Blood and lymphatic system disorders: Moderate leucopenia.
Gastrointestinal disorders: Nausea, diarrhoea, abdominal pain, dysgeusia, vomiting, stomatitis, glossitis.
Nervous system disorders: Headache.
Reproductive system and breast disorders: Vulvovaginal pruritus.
Skin and subcutaneous tissue disorders: Urticaria.

Monitoring Parameters

For bacterial vaginosis: Perform culture and susceptibility tests; consult local institutional recommendations before treatment initiation due to antibacterial resistance risks.

Drug Interactions

May increase the effects of oral anticoagulant drugs thus increase the risk of bleeding.

Action

Description: Secnidazole, a 5-nitroimidazole derivative, is an antiprotozoal and antibacterial agent. Its mechanism of action is not fully elucidated, but it is believed to be activated following its entry as inactive prodrug into the microorganisms, where it is reduced by low oxidation-reduction potential ferredoxin, thus resulting in DNA damage.
Pharmacokinetics:
Absorption: Time to peak plasma concentration: 4 hours (range: 3-4 hours).
Distribution: Volume of distribution: Approx 42 L. Plasma protein binding: <5%.
Metabolism: Metabolised in the liver via oxidation by the CYP450 enzyme system into metabolites.
Excretion: Via urine (approx 15% as unchanged drug). Elimination half-life: Approx 17 hours.

Chemical Structure

Storage

Store between 15-30°C.

MIMS Class

Antiamoebics / Other Antibiotics / Other Antiprotozoal Agents

ATC Classification

P01AB07 - secnidazole ; Belongs to the class of nitroimidazole derivatives antiprotozoals. Used in the treatment amoebiasis and other protozoal diseases.

References

Anon. Secnidazole. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 05/04/2021.

Anon. Secnidazole. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/04/2021.

Buckingham R (ed). Secnidazole. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/04/2021.

Solosec (Lupin Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 05/04/2021.

Disclaimer: This information is independently developed by MIMS based on Secnidazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com